Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases. Sitravatinib...
4 KB (257 words) - 06:01, 5 July 2024
Clinical trial number NCT02954991 for "Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung...
4 KB (191 words) - 10:34, 5 September 2024
completed in January 2024. The company’s leading drug candidates are sitravatinib and adagrasib. Mirati also has a preclinical candidate against the G12D...
5 KB (354 words) - 01:43, 28 January 2024
Selpercatinib L01EX23 Pralsetinib L01EX24 Surufatinib L01EX25 Umbralisib L01EX26 Sitravatinib L01EX27 Capivasertib QL01EX90 Toceranib L01FA01 Rituximab L01FA02 Ofatumumab...
12 KB (877 words) - 15:36, 25 January 2024